Clinical trial DS8201-A-U302
DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Daiichi Sankyo |
| EudraCT Identifier | 2018-000222-61 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03529110 |
| Inclusion criteria | HER2+. Metastatic/unresecable |
| Last update |